{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-077088","form_type":"8-K","ticker":null,"cik":"0001827087","company_name":"Vigil Neuroscience, Inc.","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.777701+00:00","generated_at":"2026-06-04T08:00:38.600813+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vigil Neuroscience Q4 2023 net loss $22.2M; positive Phase 2 interim data for iluzanebart; cash runway extended","bullets":["Q4 2023 net loss from operations $22.2M (vs $18.5M Q4 2022); full year net loss $82.6M (vs $68.3M 2022).","Cash, cash equivalents, and marketable securities $117.9M at Dec 31, 2023; cash runway extended into H2 2025.","Phase 2 IGNITE trial for iluzanebart in ALSP: positive interim data showing target engagement; enrollment completed with 20 patients; next data readout Q3 2024.","VG-3927 Phase 1 trial ongoing; interim data planned mid-2024; FDA partial clinical hold on maximum exposure limit, no expected delay.","Appointed Petra Kaufmann, M.D., as Chief Medical Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-077088","json":"https://secwatch.observer/filing/0001193125-24-077088.json","markdown":"https://secwatch.observer/filing/0001193125-24-077088.md","text":"https://secwatch.observer/filing/0001193125-24-077088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1827087/000119312524077088/0001193125-24-077088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1827087/000119312524077088/d796361d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:00:38.600813+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3c42d2825dc6cc752eef1cbd05fe6efe9f9cc3ab","claim":"Vigil Neuroscience, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"Vigil Neuroscience, Inc . (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1827087/000119312524077088/0001193125-24-077088-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}